Navigation Links
Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
Date:3/27/2008

d therapies.

TRU-015 for RA

In addition to SBI-087, Trubion also announced today the protocol details and design of the next Phase 2b study of TRU-015 for patients with RA that Trubion believes could be supportive of a registration package. The randomized, parallel, double-blind, placebo-controlled, dose regimen-finding study will evaluate the safety and efficacy of two dosing regimens administered to approximately 216 patients with active seropositive RA on a background of methotrexate. The primary outcome measurement for the TRU-015 Phase 2b study will include the American College of Rheumatology (ACR) 50 response measured at 24 weeks. Secondary outcome measurements will be ACR 20 and 70 and DAS-28 responses. This study is currently preparing for participant recruitment.

"SBI-087 strengthens our product pipeline and leverages the combined clinical experience of our strategic collaboration with Wyeth," added Dr. Thompson. "We believe that SBI-087 and TRU-015 together will play an important role in improving patient care and helping us establish category leadership in autoimmune and inflammatory diseases."

TRU-015 and SBI-087 for SLE

Wyeth intends to pursue clinical evaluation of SBI-087 in Systemic Lupus Erythematosus (SLE) and an investigational new drug filing is expected by the end of the year. As a result, Wyeth no longer intends to evaluate TRU-015 in a planned Phase 1 study originally designed to determine how the body absorbs and chemically changes a single infusion of TRU-015 in subjects with kidney disease caused by lupus. No patients were enrolled in the planned TRU-015 Phase 1 study.

TRU-015 for NHL

Trubion also announced today that Wyeth, in reviewing the competitive landscape for CD20-directed therapies, has determined not to pursue such therapies for oncology indications and, as a result, has discontinued clinical development of TRU-015 for non-Hodgkin's lymphoma.

In addition to TRU-015 and SBI-0
'/>"/>

SOURCE Trubion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Trubion Announces Initiation of Phase I/II Clinical Trial of TRU-015 for the Treatment of B-Cell Non-Hodgkins Lymphoma
2. Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis
3. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
4. Repligen Initiates Phase 3 Clinical Trial of RG1068 for Pancreatic MRI Imaging
5. Metabolex Initiates Phase 1 Trial of MBX-2982
6. Phosphagenics Initiates its Phase 2 Clinical Trial in Type 1 Diabetes
7. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
8. Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
9. Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA)
10. Phosphagenics Initiates U.S. Clinical Trials for Its Topical Retinoic Acid
11. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... May 28, 2015 Research and Markets ( ... "North America Open System MRI Market - Growth, Trends ... offering. The key players in the industry ... Siemens Healthcare and Toshiba Medical Systems ... replacing CT because of its higher sensitivity and use ...
(Date:5/29/2015)... , May 28, 2015 Research ... addition of Jain PharmaBiotech,s new report "Cardiovascular ... to their offering. Drug delivery to ... other systems because of the anatomy and physiology ... nutrients to all organs of the body. Drugs ...
(Date:5/29/2015)... 29, 2015 LifeNet Health plans to enlarge ... 2015 to more than 160 people. The ... LifeNet Health,s innovative bio-implants, which are being made more ... be served. It also is a reflection of the ... "The growth and success of LifeNet Health is a ...
Breaking Medicine Technology:North America Open System MRI Market 2014-2019 with GE, Hitachi Medical, Philips Healthcare, Siemens Healthcare and Toshiba Medical Dominating 2Global Cardiovascular Drug Delivery Market 2015 - Technologies, Markets and Companies 2Global Cardiovascular Drug Delivery Market 2015 - Technologies, Markets and Companies 3LifeNet Health to add more than 160 jobs in 2015 2
... /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex:,SVA), a leading ... today that it has commenced vaccination of,volunteers for ... pandemic,influenza H5N1 vaccine. The Phase II clinical trial ... and efficacy of the pandemic,influenza H5N1 vaccine. The ...
... 11 ImClone Systems,Incorporated (Nasdaq: IMCL ... BMY ),today announced that a Phase III ... chemotherapy (vinorelbine plus cisplatin),met its primary endpoint ... in patients with advanced non-small cell lung ...
Cached Medicine Technology:Sinovac Commences Vaccination on Volunteers for Phase II Clinical Trial on Pandemic Influenza H5N1 Vaccine 2ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 2ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 3ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 4ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 5ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 6ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 7ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 8ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study 9
(Date:5/30/2015)... 2015 On Sunday, June 14, 2015, ... – Jefferson Health will host Journey to Survivorship, a ... speaker, brunch and resources for cancer survivors and their ... the event will be Kathy LaTour, editor-at-large for Cure ... then again in 2007, LaTour provides a unique perspective ...
(Date:5/30/2015)... Chicago, Il (PRWEB) May 30, 2015 ... for Clinical Oncology (ASCO) Annual Meeting 2015 show activity ... cancer, in one case specifically against brain metastases and ... HER2+ breast cancer patients. , "I am thrilled to ... patient in her early 40s. She didn't have any ...
(Date:5/30/2015)... May 30, 2015 On Thursday, ... Dr. Charles Simone and Dr. Evan Alley both ... ‘Meet the Mesothelioma Experts’ series. The interview was ... mesothelioma centers of excellence. Drs. Simone and Alley ... Mary Hesdorffer, with whom they discussed the mesothelioma ...
(Date:5/30/2015)... 30, 2015 Nicole Blodgett, Vice ... Income Associate (DIA) designation to further her expertise ... is designed for insurance advisors, health care professionals, ... knowledge and expertise associated with the risk and ... designation is only the latest accomplishment in Nicole's ...
(Date:5/30/2015)... 2015 San Luis Obispo insurance ... offering a free analysis and consultation for anyone interested ... Disability Awareness Month, which was created by the non-profit ... United States such as Polk recognize the proclamation, and ... the possibility of disability, as well as the often-overlooked ...
Breaking Medicine News(10 mins):Health News:Abington Hospital to Host Cancer Survivorship Event 2Health News:ONT-380 has Stage IV HER2+ Breast Cancer Patient 'Worrying About Normal Stuff Again' 2Health News:ONT-380 has Stage IV HER2+ Breast Cancer Patient 'Worrying About Normal Stuff Again' 3Health News:Interview with Mesothelioma Experts, Drs. Simone and Alley Now Available on Demand 2Health News:Secura Consultants Expands Disability Insurance Expertise 2Health News:San Luis Obispo Insurance Agent Susan Polk Offering Complementary Insurance Analysis In Honor Of Disability Awareness Month 2
... efforts,to mobilize opposition to the Bush Administration,s planned $770 ... benefits in the,year ahead, the Coalition to Protect Senior ... to go on record publicly opposing,cuts to seniors, Medicare ... an especially negative impact on rural America,s nursing home,care., ...
... KALAMAZOO, Mich., May 28 Stryker Corporation,(NYSE: SYK ... following,investor conferences:, June 11, 2008 - 9:00 ... LLC Biotechnology and Medical Technology Conference New ... a.m. Pacific Time Goldman Sachs Twenty-Ninth Annual Global ...
... experts don,t endorse use of the drugs to combat ... painkillers called non-steroidal anti-inflammatory drugs (NSAIDs) appear to reduce ... medication in the class works better than the others, ... the largest of its kind, contradicts some previous studies ...
... -- WASHINGTON, DC) The American College of ... announced today a multi-year partnership to jointly sponsor ... Fla., March 2831, 2009, during ACC.09, the ACCs ... cardiovascular meeting. This will be the beginning ...
... FDA,s Janet Woodcock, MD, Provides,Practical Guidance on New ... that the Food and,Drug Administration (FDA) has new ... manufacturers can be required to develop,comprehensive risk assessment ... To help pharmaceutical companies, consultants and other drug ...
... Health Care Association: Rising Energy and Food Costs, Existing,Medicaid ... Texas, May 28 A new national study,analyzing how ... rural America,s seniors and nursing homes finds Texas will ... Texas Health Care,Association (THCA) to warn that yet another ...
Cached Medicine News:Health News:National Frontline Caregiver Coalition: Bush Administration Medicare Cuts 'Will Undercut Rural America's Nursing Home Care' 2Health News:National Frontline Caregiver Coalition: Bush Administration Medicare Cuts 'Will Undercut Rural America's Nursing Home Care' 3Health News:Stryker to Present at Investor Conferences 2Health News:Ibuprofen No Better at Reducing Alzheimer's Risk 2Health News:Ibuprofen No Better at Reducing Alzheimer's Risk 3Health News:ACC and CRF announce partnership on ACC's Innovation in Intervention: i2 Summit 2Health News:FDLI Publishes Comprehensive Handbook on Pharmaceutical Risk Management 2Health News:New Study of Bush Medicare Cuts: Texas' Rural Seniors, Nursing Homes 2nd Hardest Hit in Nation 2Health News:New Study of Bush Medicare Cuts: Texas' Rural Seniors, Nursing Homes 2nd Hardest Hit in Nation 3
Angled 13.5 mm adjustable blades. Teeth in lower jaws fit into holes in upper jaws. Grooves in lower jaw for passage of suture needles. Round knurled handle with polished finish....
Multi-curved shafts with straight blades and longitudinal serrations. Slide lock and serrated handle with polished finish. Blade length: 27 mm....
Straight shafts with 5.5 mm tying platform and 1 mm crisscross serrated tips. Wide serrated handle with polished finish....
Smooth pointed tips open to 3.0 mm. Straight shafts. Cross action. Round handle....
Medicine Products: